New Releases from NCBI BookshelfGallstone disease: diagnosis and management: Clinical guideline.Gallstone disease: diagnosis and management: Clinical guideline.
Post Content
Uncategorized
Uncategorized
New Releases from NCBI BookshelfDaratumumab (Darzalex SC): Therapeutic area: Multiple myeloma, eligible for autologous stem cell transplant: Reimbursement Review [Internet].Daratumumab (Darzalex SC): Therapeutic area: Multiple myeloma, eligible for autologous stem cell transplant: Reimbursement Review [Internet].
Post Content
Uncategorized
New Releases from NCBI BookshelfRelugolix-Estradiol–Norethindrone Acetate (Myfembree): Indication: Management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women: Reimbursement Recommendation [Internet].Relugolix-Estradiol–Norethindrone Acetate (Myfembree): Indication: Management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women: Reimbursement Recommendation [Internet].
Canada’s Drug Agency (CDA-AMC) recommends that Myfembree should be reimbursed by public drug plans for the treatment of heavy menstrual
Uncategorized
New Releases from NCBI BookshelfDupilumab (Dupixent): Indication: For the treatment of adult patients with moderate-to-severe prurigo nodularis (PN) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids: Reimbursement Recommendation [Internet].Dupilumab (Dupixent): Indication: For the treatment of adult patients with moderate-to-severe prurigo nodularis (PN) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids: Reimbursement Recommendation [Internet].
Canada’s Drug Agency (CDA-AMC) recommends that Dupixent be reimbursed by public drug plans for the treatment of adult patients with
Uncategorized
New Releases from NCBI BookshelfCipaglucosidase Alfa (Pombiliti) With Miglustat (Opfolda): Indication: Cipaglucosidase alfa is indicated in combination with the enzyme stabilizer Opfolda (65 mg miglustat capsule) for the treatment of adult patients with late-onset Pompe disease (acid α-glucosidase [GAA] deficiency) weighing ≥ 40 kg. Miglustat is an enzyme stabilizer indicated in combination with Pombiliti (cipaglucosidase alfa) for the treatment of adult patients with late-onset Pompe disease (acid α-glucosidase [GAA] deficiency) weighing ≥ 40 kg. Cipaglucosidase alfa must be used in combination with 65 mg miglustat capsules: Reimbursement Recommendation [Internet].Cipaglucosidase Alfa (Pombiliti) With Miglustat (Opfolda): Indication: Cipaglucosidase alfa is indicated in combination with the enzyme stabilizer Opfolda (65 mg miglustat capsule) for the treatment of adult patients with late-onset Pompe disease (acid α-glucosidase [GAA] deficiency) weighing ≥ 40 kg. Miglustat is an enzyme stabilizer indicated in combination with Pombiliti (cipaglucosidase alfa) for the treatment of adult patients with late-onset Pompe disease (acid α-glucosidase [GAA] deficiency) weighing ≥ 40 kg. Cipaglucosidase alfa must be used in combination with 65 mg miglustat capsules: Reimbursement Recommendation [Internet].
Canada’s Drug Agency (CDA-AMC) recommends that Pombiliti with Opfolda be reimbursed by public drug plans for the treatment of adult
Uncategorized
New Releases from NCBI BookshelfDupilumab (Dupixent): Indication: Add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyposis inadequately controlled by systemic corticosteroids and/or surgery: Reimbursement Recommendation [Internet].Dupilumab (Dupixent): Indication: Add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyposis inadequately controlled by systemic corticosteroids and/or surgery: Reimbursement Recommendation [Internet].
Canada’s Drug Agency (CDA-AMC) recommends that Dupixent be reimbursed by public drug plans for the treatment of severe chronic rhinosinusitis
Uncategorized
New Releases from NCBI BookshelfSemaglutide (Wegovy): Indication: As an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of:: Reimbursement Recommendation [Internet].Semaglutide (Wegovy): Indication: As an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of:: Reimbursement Recommendation [Internet].
Canada’s Drug Agency (CDA-AMC) recommends that Wegovy be reimbursed by public drug plans for chronic weight management if certain conditions
Uncategorized
New Releases from NCBI BookshelfPortable CT for Use in the Hospital: Health Technologies [Internet].Portable CT for Use in the Hospital: Health Technologies [Internet].
Canada’s Drug Agency (CDA-AMC) is examining the role of portable CT use in Canada.
Uncategorized
New Releases from NCBI BookshelfDurvalumab (Imfinzi): Indication: As monotherapy, for the treatment of adult patients with limited-stage small cell lung cancer whose disease has not progressed following platinum-based chemoradiation therapy: Reimbursement Recommendation [Internet].Durvalumab (Imfinzi): Indication: As monotherapy, for the treatment of adult patients with limited-stage small cell lung cancer whose disease has not progressed following platinum-based chemoradiation therapy: Reimbursement Recommendation [Internet].
Canada’s Drug Agency (CDA-AMC) recommends that Imfinzi be reimbursed by public drug plans for the treatment of adults with limited-stage
Uncategorized
New Releases from NCBI BookshelfComparing Ways to Reduce High Blood Pressure in Patients from Different Racial and Ethnic Groups—The RICH LIFE Project [Internet].Comparing Ways to Reduce High Blood Pressure in Patients from Different Racial and Ethnic Groups—The RICH LIFE Project [Internet].
Disparities in the control of hypertension (HTN) and other cardiovascular disease risk factors are well-documented in the United States, even
